Shares of Zura Bio Limited (NASDAQ:ZURA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $17.00.
A number of analysts have recently issued reports on ZURA shares. William Blair initiated coverage on shares of Zura Bio in a report on Wednesday, July 8th. They issued an “outperform” rating on the stock. Weiss Ratings upgraded Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday. Guggenheim reissued a “buy” rating on shares of Zura Bio in a research report on Friday. Wedbush raised their price target on Zura Bio from $15.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st.
Get Our Latest Stock Report on ZURA
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Montanova Capital LLC lifted its holdings in shares of Zura Bio by 4.1% during the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company’s stock worth $55,714,000 after buying an additional 376,000 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Zura Bio by 3,007.7% in the first quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after acquiring an additional 132,130 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Zura Bio in the first quarter valued at about $4,483,000. ADAR1 Capital Management LLC increased its position in Zura Bio by 12.2% during the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock worth $3,751,000 after acquiring an additional 68,338 shares during the period. Finally, EcoR1 Capital LLC bought a new position in Zura Bio during the first quarter worth about $7,019,000. 61.14% of the stock is owned by institutional investors.
Zura Bio Trading Up 4.9%
NASDAQ ZURA opened at $4.04 on Friday. Zura Bio has a 12 month low of $3.25 and a 12 month high of $7.44. The stock has a 50-day simple moving average of $4.66 and a 200 day simple moving average of $5.24. The company has a market capitalization of $387.15 million, a PE ratio of -3.61 and a beta of 0.01.
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). As a group, sell-side analysts predict that Zura Bio will post -0.82 earnings per share for the current fiscal year.
About Zura Bio
Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.
Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.
Featured Stories
- Five stocks we like better than Zura Bio
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
